Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies

Maarga Mind Care launches integrative day care program to bridge mental health recovery gap

New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery

Plasmidsaurus expands RNA-Seq in Europe, partners with Genovis for ambient RNA shipping

The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics

Medera doses final patient in high-dose HFpEF gene therapy trial

Heart failure affects an estimated 64.3 million people worldwide

Teva moves within reach of investment grade as S&P upgrades credit rating & Moody’s positive

AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment

Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

Gandhar Oil Refinery (India) reports Q1 FY26 consolidated PAT lower at Rs. 26.1 Cr YoY

Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy

Capricor’s BLA for Deramiocel received Priority Review in March 2025